Drugs / Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02483000 | Feb 2017 → Nov 2019 | Burkitt lymphoma, diffuse large B-cell lymphoma, indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02483000 ↗ |
| Modality | Protein / enzyme biologic | “B9E9-fusion protein” NCT02483000 ↗ |
| Route | Intravenous | “Given IV” NCT02483000 ↗ |